Friday, January 29, 2016

SESSION 1: LUMINAL GASTROINTESTINAL DISEASE
Moderator: John E. Pandolfino, MD, MSCI, FACG

POEM for Achalasia: Is This the Better Option?
John E. Pandolfino, MD, MSCI, FACG
Assess outcomes for medical, endoscopic, and surgical interventions for the treatment of achalasia.

GERD and Extraesophageal Manifestations
Kenneth R. DeVault, MD, FACG
Differentiate extraesophageal symptoms of GERD from other disorders and recommend treatment.

Management of Barrett’s Esophagus
Nicholas J. Shaheen, MD, MPH, FACG, FASGE
Discuss surveillance recommendations and therapy for the management of Barrett’s esophagus.

Celiac Disease versus Gluten Intolerance or Sensitivity
Sheila E. Crowe, MD, FACG
Distinguish clinical and serologic findings in the setting of gluten exposure and facilitate management.

Fecal Microbiota Transplant in IBD
Christina M. Surawicz, MD, MACG
Discuss practical issues related to the performance of fecal transplantation in patients with IBD.

SESSION 2: ENDOSCOPY
Moderator: Immanuel K.H. Ho, MD, FACG, FASGE

What to Do with Luminal Foreign Bodies
David A. Greenwald, MD, FACG, FASGE
Discuss the endoscopic tools and techniques for managing foreign bodies.

Enteral Stenting
John R. Saltzman, MD, FACG, FASGE
Appraise the efficacy, safety, and outcomes of endoluminal stenting.

Endoscopic Advances for the Management of Obesity
Gregory G. Ginsberg, MD, FACG, FASGE
Describe the safety and efficacy of endoscopic therapies for weight reduction.

Management of Indeterminate Biliary Strictures
Douglas G. Adler, MD, FACG, FASGE
Analyze the recent advances in endoscopic management of biliary strictures.

PRACTICE MANAGEMENT SESSION
Moderator: Costas H. Kefalas, MD, MMM, FACG, FASGE

Risk Management for Prescribing GI Medications
Scott M. Tenner, MD, MPH, JD, FACG, FASGE
Identify and manage legal risks of certain GI medications.

Should I Join an ACO or Not?
G. Anton Decker, MBBCh, MRCP, MHA, CPE, FACG
Compare the pros and cons of joining an ACO.

SGR Repeal and the Merit-Based Incentive Payment System (MIPS)
Caroll D. Koscheski, MD, FACG
Explain the new Merit-Based Incentive Payment System (MIPS).
Incorporating Quality Metrics into Your Practice
Irving M. Pike, MD, FACG, FASGE
Identify and integrate key quality metrics into the GI practice.

Saturday, January 30, 2016

SESSION 3: HEPATOLOGY
Moderator: David E. Bernstein, MD, FACG

Current and Emerging Therapies for Hepatitis B
Tram T. Tran, MD, FACG
Describe the current and forthcoming treatments of hepatitis B.

Hepatitis C in Special Populations
David E. Bernstein, MD, FACG
Discuss treatment approaches for special populations with hepatitis C.

Drug-Induced Liver Disease
William M. Lee, MD, FACG
Outline the current management of drug-induced liver disease.

Emerging Management of NASH
Richard K. Sterling, MD, MSc, FACG
Define the emerging treatment options for NASH.

SESSION 4: FUNCTIONAL BOWEL DISORDERS
Moderator: Jennifer A. Christie, MD, FASGE

The Role of the Gut Microbiome on Functional Bowel Symptoms
William D. Chey, MD, FACG
Explain the interactions between the gut microbiota, the enteric nervous system and functional bowel symptoms.

Gastroparesis or Cyclic Vomiting: Does it Matter for Treatment?
Brian E. Lacy, MD, PhD, FACG
Contrast the management of gastroparesis and cyclic vomiting syndrome.

Novel Options for the Management of Fecal Incontinence
Arnold Wald, MD, MACG
Discuss the latest advances in the treatment of fecal incontinence.

Irritable Bowel Syndrome in 2016
Amy E. Foxx-Orenstein, DO, FACG
Identify physiologic contributions to IBS symptoms and management strategies.

SESSION 5: GASTROINTESTINAL ONCOLOGY
Moderator: Carol A. Burke, MD, FACG, FASGE

Dysplasia in IBD: Update on Surveillance and Management
David T. Rubin, MD, FACG, FASGE
Appraise and apply diagnostic and therapeutic strategies in colonoscopic surveillance.

Surveillance in Hereditary Colorectal Cancer Syndromes
Carol A. Burke, MD, FACG, FASGE
Evaluate hereditary colorectal cancer syndromes and recommend surveillance approaches.

Subepithelial Lesions of the Gut: When Should I Worry?
Douglas O. Faigel, MD, FACG, FASGE
Summarize endoscopic characteristics, diagnostic methods, and therapy of subepithelial gut lesions.
BREAKOUT SESSIONS

Autoimmune Hepatitis and Overlap Syndrome
Tram T. Tran, MD, FACG

Pancreatic Cysts
James M. Scheiman, MD, FACG, FASGE
Integrate current guideline(s) in the management of pancreatic cystic lesions.

“Obscure” GI Bleeding
Lauren B. Gerson, MD, MSc, FACG, FASGE
Summarize effective diagnostic and efficient management strategies for the treatment of obscure GI bleeding.

Preventing Post-operative Recurrence in Crohn’s Disease
Miguel D. Regueiro, MD, FACG
Assess the benefits of medical therapy in the perioperative and postoperative patient.

Tricks of the Trade: The Difficult ERCP Cannulation
Douglas G. Adler, MD, FACG, FASGE
Identify endoscopic methods to improve cannulation success.

SESSION 6: INFLAMMATORY BOWEL DISEASE
Moderator: David T. Rubin, MD, FACG, FASGE

Can We Predict the Course of Crohn’s Disease and Why Does It Matter?
Stephen B. Hanauer, MD, FACG
Recognize the genotypic and phenotypic factors that affect disease behavior.

Management of Refractory Crohn’s Disease
David T. Rubin, MD, FACG, FASGE
Describe the management of the patient with refractory Crohn’s disease.

IBD Therapy in the Patient with Infection
Miguel D. Regueiro, MD, FACG
Determine whether IBD therapy should be continued in the patient with infection.

Managing IBD During and After Pregnancy
Sunanda V. Kane, MD, MSPH, FACG
Discuss the approach to IBD therapy during and after pregnancy.

Sunday, January 31, 2016

SESSION 7: ENDOSCOPY
Moderator: John R. Saltzman, MD, FACG, FASGE

Anti-coagulants/Anti-platelet Agents and GI Bleeding
Neena S. Abraham, MD, MSc (EPID), FACG, FASGE
Summarize pre- and post-endoscopic management recommendations for the treatment of GI bleeding.

The Flat Polyp
Tonya R. Kaltenbach, MD, MS, FACG, FASGE
Characterize endoscopic features of flat polyps and apply resection techniques.

Minimizing Risks in ERCP
John R. Saltzman, MD, FACG, FASGE
Apply endoscopic and non-endoscopic means to prevent infection and post-procedure pancreatitis.

Esophageal Leaks, strictures, and Emergencies
Gregory G. Ginsberg, MD, FACG, FASGE
Review the efficacy and risks of various endoscopic interventions.

EUS – Pushing the Limits
Douglas O. Faigel, MD, FACG, FASGE
Describe current and emerging therapeutic options and summarize clinical outcomes in EUS.
Friday, March 18, 2016

Microbiome: Role in Health and Disease  
*Lawrence J. Brandt, MD, MACG*  
Describe the involvement of gut microbiota in maintenance of overall health.

Prebiotics, Probiotics, Synbiotics, and Antibiotics – Role in IBS  
*William D. Chey, MD, FACG*  
Formulate a treatment plan targeting the gut microbiota in patients with irritable bowel syndrome.

New Approaches in the Treatment of IBD  
*Oriana M. Damas, MD*  
Determine appropriate and cost-effective treatment goals for IBD, utilizing new and evolving therapies.

Update on Pancreatic Cysts  
*Peter V. Draganov, MD, FACG*  
Recognize the types of pancreatic cysts and their malignancy potential.

Advanced Endoscopic Imaging  
*Michael B. Wallace, MD, MPH, FACG*  
Discuss the utility of new technology such as high definition white light, NBI, and chromoendoscopy to improve management of premalignant mucosal diseases.

Strategies to Enhance Patient Engagement  
*James S. Leavitt, MD, FACG*  
Create real and measurable value that will be critical for future success.

Saturday, March 19, 2016

HBV: Update and Treatment Guidelines  
*Virginia Clark, MD, MS*  
Identify the appropriate therapy for patients with chronic hepatitis B infection.

Update in HCV Treatment  
*Kalyan Ram Bhamidimarri, MD, MPH*  
Identify the appropriate treatment choices for various HCV genotypes.

Alcoholic Liver Disease  
*Paul Martin, MD, FACG*  
Define the current definitions for diagnosis of alcoholic liver disease and alcoholic hepatitis.

Management of PSC: Update and Guidelines  
*Cynthia Levy, MD*  
Apply the most recent guidelines for diagnosis of patients with PSC.

Severe Acute Pancreatitis  
*Chris E. Forsmark, MD, FACG*  
Develop a systematic management approach to severe acute pancreatitis.

Neuroendocrine Tumors  
*Steven E. Rodgers, MD, PhD*  
Improve the ability to accurately stage neuroendocrine tumors.
Sunday, March 20, 2016

**Ischemic Colitis**  
*Lawrence J. Brandt, MD, MACG*  
Interpret recommendations from most recent guidelines for the diagnosis of ischemic colitis.

**Colon Cancer Syndromes**  
*Daniel A. Sussman, MD, MSPH*  
Describe the appropriate management of colon cancer syndromes as recommended in recent guidelines.

**Management of Visceral Pain**  
*William D. Chey, MD, FACG*  
Apply appropriate strategies for the management of visceral pain, including medical and behavioral therapies.

**Update on *C. difficile* Colitis**  
*David H. Kerman, MD*  
Determine the most appropriate treatment plan for patients with *C. difficile*, including the role of surgical therapy and fecal transplantation.

**Barrett’s Esophagus – Ablate Everyone?**  
*Herbert C. Wolfsen, MD, FACG*  
Utilize the most accurate endoscopic techniques to identify and characterize Barrett’s esophagus.

**Managing Short Bowel Syndrome**  
*Patricia M. Byers, MD*  
Discuss the role of intestinal transplantation in managing patients with short bowel syndrome.
Friday, March 4, 2016

POEM With the Flexible Scope as a Treatment for Achalasia and Zenker's Diverticulum  
Abraham Mathew, MD  
Describe the per oral approach for myotomy; describe endoscopic diverticulotomy; and identify complications related to POEM.

Saturday, March 5, 2016

Physician Burnout: How the Gastroenterologist Can Cope With the Stresses of Modern Practice  
Christina M. Surawicz, MD, MACG  
Describe definitions of burnout and discuss its contributing factors and identify ways to recognize, prevent and treat burnout.

Chronic Abdominal Pain: It's Not Always Visceral  
Lawrence R. Schiller, MD, FACG  
Evaluate and manage patients presenting with chronic abdominal pain.

Dietary Contributions to Symptoms and Treatment of IBS: Is There a “Food Print” in this Disease?  
Paul Moayyedi, BSc, MB ChB, PhD, MPH, FACG  
Compare current data supporting a dietary cause of IBS symptoms; examine the validity of dietary manipulations in IBS treatment and discuss the direction of future research in dietary manipulation for IBS.

Changing Face of Liver Transplantation in the United States  
Nigel Girgrah, MD, PhD  
Identify the evolving indications for liver transplantation in our country and future advances in the field.

Use of Biomarkers in the Diagnosis and Prognosis of Inflammatory Bowel Disease  
John F. Valentine, MD  
Incorporate into practice the advances made in the biochemistry of IBD.

Adapting to Future Health Care Delivery Systems  
Kenny J. Cole, MD  
Explain the methods and metrics used by large provider organizations in designing health care delivery systems.

Fellow Presentations: Case Studies and Original Research From Tulane and LSU Fellows  
Illustrate difficult GI management issues using case presentations.

Diagnosis and Management of Chronic Pancreatitis  
Stephen T. Amann, MD, FACG  
Summarize the challenges of identifying, treating and monitoring this growing but under-recognized cohort.

Nonsurgical Treatment of Obesity and the Gastroenterologist  
Frank Greenway, MD  
Evaluate the patient selection, drug choices and therapeutic challenges of this growing epidemic.

PBC and NASH: Progress on the Horizon  
Mary E. Rinella, MD, FACG  
Discuss the diagnosis, illness burden, prognostication and advances in the treatment of PBC and NASH.
Saturday, June 25, 2016

SESSION 1: ENDOSCOPY
Moderator: Vanessa M. Shami, MD, FACG

Update on the Management of Anticoagulants and Endoscopy
Vivek Kaul, MD, FACG
Assess the risk of bleeding in patients on anticoagulants and antiplatelet agents prior to endoscopic procedures and discuss the cardiovascular implications of modifying therapy during the peri-endoscopic setting.

New Approaches in the Management of Non-Variceal Upper Gastrointestinal Bleeding
Bryan G. Sauer, MD, MSc
Describe the different endoscopic tools available for hemostasis, including over-the-scope clipping, radiofrequency ablation for GAVE, and EUS-guided hemostasis.

Management of Recurrent and Refractory Esophageal Strictures
Vanessa M. Shami, MD, FACG
Define “recurrent” vs. “refractory” esophageal strictures and evaluate the different modalities available to manage these strictures with steroid injection, needle knife, and stenting.

SESSION 2: COLON
Moderator: Sergey V. Kantsevoy, MD, PhD

Navigating Through Difficult Colons
Firas H. Al-Kawas, MD, FACG
Recognize the common complications associated with the difficult colonoscopy and learn how to avoid these complications.

Tips to Improve Adenoma Detection Rates During Colonoscopy
Aasma Shaukat, MD, MPH, FACG
Identify the quality standards for colonoscopy and discuss strategies and emerging technologies to improve adenoma detection rates.

Handling Large Sessile or Flat Polyps
Sergey V. Kantsevoy, MD, PhD
Describe optimal techniques to remove large sessile or flat polyps, manage potential complications, and review surveillance protocols after removal of large polyps.

SESSION 3: ESOPHAGUS
Moderator: Fouad J. Moawad, MD, FACG

Eosinophilic Esophagitis – What to Do When Topical Steroids Fail?
Fouad J. Moawad, MD, FACG
Summarize the alternative treatment options in steroid refractory EoE patients including specialized diets and esophageal dilation for fibrostenotic strictures; and describe the role of emerging therapies, including biologic and interleukin agents.

GERD – What Is the Next Step After Incomplete Response to PPI?
Michael F. Vaezi, MD, PhD, MSc(Epi), FACG
Define refractory GERD and identify the expected response, escalating therapy, and treatment options in a patient with suboptimal response to PPI.

Barrett’s Esophagus – Who Should Undergo Surveillance and What Techniques Can Improve Detection of Dysplasia?
Prateek Sharma, MD, FACG
Explain current recommendations for surveillance intervals depending on Barrett’s length and identify evidence-based methods which may improve detection of dysplasia.
SESSION 4: IBD
Moderator: Matilda N. Hagan, MD

Systemic Complications in IBD Patients
Raymond K. Cross, Jr., MD, MS
Recognize the potential systemic complications and the role of multi-disciplinary management in IBD.

Biologics in 2016: How Do We Select the Most Appropriate Agent?
Gary R. Lichtenstein, MD, FACG
Identify new biologic agents used in IBD, their mechanism of action, and describe their treatment-related complications.

Utility of Biomarkers in IBD
Matilda N. Hagan, MD
Discuss the role for various fecal and serological biomarkers in the diagnosis of IBD and recognize the utility of biomarker assays (drug metabolites or antibodies against the drugs) in IBD treatment.

Hepatitis C: Drugs of Choice for G1-6
Bruce A. Luxon, MD, PhD, FACG
Explain new developments in HCV management with interferon free regimens and the potential side effects and drug resistant mutations.

Is it Celiac Disease or Gluten Sensitivity?
Mark T. DeMeo, MD, FACG
Outline the pathogenesis and the best current testing methods to diagnose celiac disease and gluten sensitivity.

The Difficult ERCP: Tips to Succeed
Andrew Y. Wang, MD, FACG
Define conditions which are predictors for difficult cannulation such as altered anatomy, diverticula, and ampulary stenosis; and describe techniques which would facilitate cannulation when traditional methods are unsuccessful.

Sunday, June 26, 2016

SESSION 5: FUNCTIONAL AND LUMINAL BOWEL DISORDERS
Moderator: Brooks D. Cash, MD, FACG

Management of Dyspepsia
John K. DiBaise, MD, FACG
Define dyspepsia, recognize alarm features which would prompt further evaluation, and compare evidence-based treatment for the dyspeptic patient.

Treatment of IBS – Diet or Drugs?
Brooks D. Cash, MD, FACG
Identify treatment options and compare clinical response in the IBS patient to include specialized diets, tricyclic antidepressants, and antispasmodics.

H. pylori – How to Handle It if Refractory to the Initial Treatment Course?
David A. Peura, MD, MACG
Recognize the epidemiology of refractory H. pylori and describe current management options in patients who are refractory to an initial course of treatment.

Clostridium difficile – When to Use FMT?
Lawrence J. Brandt, MD, MACG
Evaluate the role of FMT in C. difficile via upper versus lower GI tract and compare response of FMT in refractory versus recurrent C. difficile.
SESSION 6: PANCREATICOBILIARY
Moderator: Vanessa M. Shami, MD, FACG

Incidental Pancreatic Cysts: When to Survey, Sample, Resect, or Ablate?
Anne Marie Lennon, MD
Describe the most common incidentally found pancreatic cystic lesions (including imaging characteristics) and discuss the factors (size, CEA, cytology, imaging criteria) that would prompt sampling resection, or ablation.

Recurrent Acute Pancreatitis: Work-up and Management
Gregory A. Coté, MD, MS
Diagnose and determine the causative factors of acute pancreatitis, discuss the best modalities for estimating the severity of pancreatitis, and identify patients who require endoscopic and/or surgical care.

Evaluation and Management of Refractory Biliary Stricture
J. David Horwhat, MD, FACG
Describe refractory biliary strictures, discuss the imaging and procedural work-up, and summarize the management of refractory biliary strictures including stenting.

SESSION 7: LIVER
Moderator: Paul J. Thuluvath, MD, FACG

NASH: Progress in the Last Decade
Mitchell L. Shiffman, MD, FACG
Explain the prevalence, natural history, and pathogenesis of NASH, and discuss the treatment options and research in progress.

Alcoholic Hepatitis
Paul J. Thuluvath, MD, FACG
Identify current prognostic models, treatment options, and the role of liver transplantation in alcoholic hepatitis.

What Is Acute-on-Chronic Liver Failure?
David E. Bernstein, MD, FACG
Define acute-on-chronic liver failure, summarize prognostic variables, treatment strategies, and ongoing research.
Saturday, August 27, 2016

SESSION 1: FUNCTIONAL GI DISORDERS
Moderator: William D. Chey, MD, FACG

Management of Functional Dyspepsia
Amy S. Oxentenko, MD, FACG
Evaluate the latest evidence on management of functional dyspepsia.

Pharmacological Management of IBS
Brian E. Lacy, MD, PhD, FACG
Identify the appropriate pharmacological agent for IBS.

Dietary and Other Non-pharmacological Management of IBS
William D. Chey, MD, FACG
Describe the role of dietary and mental health based therapies for IBS.

SESSION 2: COLITIS AND IBD
Moderator: Sunanda V. Kane, MD, MSPH, FACG

Options for IBD Failing Anti-TNF
Sunanda V. Kane, MD, MSPH, FACG
Interpret the natural history and treatment options for patients failing anti-TNF therapy.

Detection and Management of Dysplasia in IBD Surveillance
David T. Rubin, MD, FACG
Explain detection and management of dysplasia in IBD surveillance.

Spectrum of Diverticular Disease: SUDD, SCAD
Byron P. Vaughn, MD
Summarize the expanding spectrum of diverticular disease and treatment options.

SESSION 3: ESOPHAGEAL DISORDERS
Moderator: Prateek Sharma, MD, FACG

Hard-to-Treat GERD: Endoscopic or Surgical Management?
Kenneth K. Wang, MD, FACG
Identify endoscopic and surgical options for difficult-to-treat GERD.

Management of EoE
Ikuo Hirano, MD, FACG
Explain the natural history and treatment options for EoE.

Surveillance and Management of Barrett's Esophagus
Prateek Sharma, MD, FACG
Discuss the guidelines and controversies in screening and surveillance for Barrett's esophagus.

SESSION 4: ENDOSCOPY AND PANCREAS
Moderator: Martin L. Freeman, MD, FACG

Approach to Cystic Lesions of the Pancreas
Nalini M. Guda, MD
Assess the best approach to cystic lesions of the pancreas.

Updates in the Management of Acute Pancreatitis
Martin L. Freeman, MD, FACG
Evaluate recent evidence on fluid management, nutrition, and early management of acute pancreatitis.
Management of Anti-thrombotic Agents for Endoscopy
John R. Saltzman, MD, FACG
Discuss the guidelines and practical approach to anti-thrombotic management during endoscopy.

High Resolution Esophageal Manometry: Case-based Approach
Ikuo Hirano, MD, FACG
Illustrate the indications, interpretation, and management of HRM using a case-based approach.

Use of Anti-TNF Antibodies and Other Serologies for Managing IBD
Christopher J. Shepela, MD, MSc
List the indications and clinical application of anti-TNF antibodies and other prognostic serological markers for IBD management.

EMR and ESD: Tools and Techniques
John R. Saltzman, MD, FACG
Describe evidence behind safe and effective ESD and EMR techniques.

Diet, FMT, and Other Non-pharmacological Management Options for IBD
Tedd P. Cain, MD, FACG
Discuss dietary advice, use of FMT, and other non-pharmacological therapies in the management of IBD.

Sunday, August 28, 2016

SESSION 5: COLON
Moderator: Aasma Shaukat, MD, MPH, FACG

Effective and Safe Polypectomy Techniques
Douglas K. Rex, MD, MACG
Recognize safe and effective polypectomy techniques for small and large/complex polyps.

Technology and Interventions to Improve ADR
Aasma Shaukat, MD, MPH, FACG
Evaluate the latest evidence on technology and other interventions to improve ADRs.

Natural History and Approach to Serrated Lesions
Andrew R. Reinink, MD
Discuss natural history, optimal management, and follow-up of serrated lesions in the colon.

Practical Approach to Genetic Syndromes in CRC
Carol A. Burke, MD, FACG
Identify approaches to diagnosing and managing hereditary CRC syndromes.

SESSION 6: LIVER DISEASE
Moderator: Bruce R. Bacon, MD, FACG

Challenges in Management of Hepatitis C
Bruce R. Bacon, MD, FACG
Discuss the updates and challenges in hepatitis C treatment.

Updates in Treatment of Hepatitis B
Paul Y. Kwo, MD, FACG
Describe the indications, agents, duration, and follow-up of therapies for hepatitis B.

Management of Alcoholic Liver Disease
Mark W. Russo, MD, MPH, FACC
Recognize spectrum of alcoholic liver disease and optimal options for management.

Practical Approach and Management of Liver Lesions
John J. Poterucha, MD
Explain the clinical spectrum of liver lesions and practical approach to management.
Saturday, September 10, 2016

SESSION 1: UPPER GI

**RFA for Barrett’s With Low Grade Dysplasia**  
*Nicholas J. Shaheen, MD, MPH, FACG*  
Identify the benefits and limitations of RFA in dysplastic Barrett’s metaplasia and summarize surveillance protocols after eradication.

**Managing GERD: Beyond PPIs**  
*Michael S. Smith, MD, MBA*  
Describe therapies for gastroesophageal reflux disease that is refractory to proton pump inhibitor therapies.

**Diagnosing and Managing Gastroparesis**  
*Henry P. Parkman, MD, FACG*  
Discuss clinical symptoms, diagnosis and treatment approach in patients with gastroparesis.

SESSION 2: LIVER

**Hepatic Encephalopathy Treatments: Beyond Lactulose**  
*Jasmohan S. Bajaj, MD, MSc, FACG*  
Apply medical and dietary treatment alternatives to the patient who has hepatic encephalopathy and is refractory to lactulose.

**Managing the Hospitalized Cirrhosis Patient**  
*Neeral L. Shah, MD*  
Differentiate strategies in hospitalized patients with complications of portal hypertension and an imbalance in coagulation.

**Hepatitis B Treatment Pearls**  
*Fredric D. Gordon, MD*  
Summarize the latest treatment options and algorithms for challenging patients with hepatitis B.

**Keynote Lecture – Leading Teams: 20 Bad Habits and How to Avoid Them**  
*Kenneth R. Devault, MD, FACG*  
Utilize a toolbox of techniques relevant to your life and professional practice.

SESSION 3: PANCREATO-BILIARY

**Managing Chronic Pancreatitis**  
*Doumit S. BouHaidar, MD*  
Evaluate endoscopic diagnosis and management options for patients presenting with chronic pancreatitis.

**Managing Anti-Coagulation in Endoscopy**  
*Dushant S. Uppal, MD, MSc*  
Explain the use and management of anticoagulation medications in patients undergoing endoscopy.

**ERCP Cannulation: Tips and Tools of the Trade**  
*Ann Marie Joyce, MD*  
Identify advances associated with the effective performance of ERCP.
SESSIONS FOR GI NURSES

Jazz Up Your GI Journey with SGNA
Kristine Barman, BSN, RN, CGRN

Didactic Presentation of the Anatomy, Physiology, and Pathophysiology of Common Disorders Seen During ERCP and EUS
Jeanine Penberthy, MSN, RN, CGRN

SESSION 4: GI PRACTICE MANAGEMENT

Surviving Practice Mergers
Daniel J. Pambianco, MD, FACG
Discuss the current climate in private practice gastroenterology with the formation of merged large group practices.

Using Social Media and the Web to Promote Your Practice
Ryan D. Madanick, MD
Analyze the steps required to implement social media into your website and how to use it to grow your practice and manage your professional reputation.

SESSION: FELLOWS’ DEBATE AND CASE PRESENTATIONS: “THE DUEL AT THE LODGE”
Moderator: Patrick G. Northup, MD, MHS
Moderator: Mitchell L. Schubert, MD, FACG

Pros and Cons Debate – University of Virginia Fellows
Case Presentations – Virginia Commonwealth University Fellows

Sunday, September 11, 2016

SESSION 5: IBD

Treatment Options for Severe IBD
Stephen B. Hanauer, MD, FACG
Recognize indications and proper uses of the new therapeutic agents available in the care of IBD patients with advanced disease.

The Future Role of Biosimilars: An Unknown Frontier in IBD Treatment
Miguel D. Regueiro, MD, FACG
Assess the impact of biosimilars and their role in future IBD treatment regimens.

When and How to Use Chromoendoscopy
Samir A. Shah, MD, FACG
Describe the indications for the usage of chromoendoscopy to detect dysplasia in patients with IBD.

SESSION 6: LOWER GI

Indications and Use of Small Bowel Imaging (Capsule and Radiology)
Andrew P. Copland, MD
Compare the roles of various small bowel imaging modalities in the diagnosis and management of gastrointestinal disorders.

Diagnosing Polyposis Syndromes and Referring to Genetics
Carol A. Burke, MD, FACG
Differentiate various polyposis syndromes and develop strategies for diagnosis, management and referring for further genetic work-ups.

Devices to Improve Colon Polyp Detection
Vivek Kaul, MD, FACG
Summarize new devices and techniques for successful polyp detection.
Friday, December 2, 2016

HBV – Natural History and Management  
Mitchell L. Shiffman, MD, FACG
Discuss the natural history of hepatitis B, HBV serologies, the different immune stages of the disease, and screening recommendations for HCC in patients with HBV.

HBV – Treatment  
Mark W. Russo, MD, MPH, FACG
Explain current recommendations for the treatment of HBV and summarize the use of anti-HBV drugs to minimize transmission risk during pregnancy and to prevent reactivation of occult HBV during immunosuppression.

HCV – Epidemiology, Screening, Natural History, and Extra-hepatic Manifestations  
Paul Y. Kwo, MD, FACG
Describe the epidemiology of HCV, screening recommendations, and the natural history of HCV.

HCV – Assessing the Patient Prior to Treatment: Diagnostic Testing and Staging  
Tram T. Tran, MD, FACG
Assess currently available assays used in the diagnosis of hepatitis C and discuss current modalities available for staging fibrosis in patients with HCV.

HCV – Treatment of Genotype 1: Now and in the Future  
Mark W. Russo, MD, MPH, FACG
Summarize the current and future management options for patients with HCV genotype 1, including patients with cirrhosis.

HCV – Treatment of Genotypes 2, 3, and 4: Now and in the Future  
David E. Bernstein, MD, FACG
Analyze the current and future management options for patients with HCV genotypes 2, 3, and 4, including cirrhosis.

HCV – Retreatment of DAA Failures  
Tram T. Tran, MD, FACG
Identify how to approach patients who have failed HCV treatment with the current DAA therapies and the role viral mutations/resistance may play in this process.

HCV – The Nuts and Bolts of Treatment  
April G. Morris, FNP
Outline how to prepare patients for HCV treatment, obtain medication approval from the insurance carriers, and monitor patients during treatment.

Treatment of Patients With Decompensated Cirrhosis and Liver Transplant Recipients  
Paul Y. Kwo, MD, FACG
Differentiate HCV treatment in HCV patients with decompensated cirrhosis, which patients should not be treated, and how to manage HCV after liver transplantation.

Approach to HCV Treatment in Patients With HCC  
Tram T. Tran, MD, FACG
Evaluate the relationship between HCV and HCC, discuss screening strategies for evaluation of HCC, and when to consider treatment of HCV in patients with HCC.

HCV in Patients With Chronic Renal Failure  
David E. Bernstein, MD, FACG
Explain the epidemiology and natural history of HCV in patients with end-stage renal disease and the treatment options available for these patients.
Treatment of Patients With HCV and HIV

Paul Y. Kwo, MD, FACG

Discuss the epidemiology and natural history of HCV in patients with HIV and the treatment options available for these patients.

The Impact of Curing HCV on the Liver and the Extra-hepatic Manifestations of Chronic HCV

Mitchell L. Shiffman, MD, FACG

List how HCV impacts other organs outside the liver and the impact of curing HCV on these extra-hepatic manifestations.
Saturday, December 3, 2016

SESSION 1: INFLAMMATORY BOWEL DISEASE
Moderator: Stephen B. Hanauer, MD, FACG

Disease Assessment in Crohn's Disease and Ulcerative Colitis
Stephen B. Hanauer, MD, FACG
Describe the clinical evaluation of IBD, including blood and stool biomarkers, endoscopic and radiographic imaging.

Preventive Care and Monitoring of the IBD Patient
Francis A. Farraye, MD, MSc, FACG
Discuss the standard recommendations for baseline immunizations and health care monitoring in the IBD patient.

Moderate to Severe Crohn's Disease and Ulcerative Colitis: What Are the Treatment Options for 2017?
Douglas C. Wolf, MD, FACG
List the current and new treatment options with a focus on biologic therapy.

Diagnosis and Management of Extraintestinal Manifestations of IBD
Millie D. Long, MD, MPH, FACG
Explain the diagnosis and treatment of the skin, eye, and other extraintestinal manifestations of IBD.

SESSION 2: NUTRITION AND OBESITY MANAGEMENT
Moderator: John K. DiBaise, MD, FACG

Nutritional Management of the Hospitalized Patient: Insights From the Guidelines
Stephen A. McClave, MD
Identify new approaches to the management of the hospitalized patient.

Management of Challenges in the Post-operative Bariatric Patient
John K. DiBaise, MD, FACG
Describe post-bariatric surgical challenges.

Nutritional Management of the Outpatient: Including Elimination Diets, FODMAP, SCD, and Supplements
Christina Y. Ha, MD
Evaluate the risks and benefits of dietary supplements, as well as new elimination and related diets.

SESSION 3: THE GUT MICROBIOME AND GASTROINTESTINAL DISEASE
Moderator: Christina M. Surawicz, MD, MACG

The Clostridium difficile Epidemic and the Immunocompromised Patient
Neil H. Stollman, MD, FACG
Recognize the epidemiology of C. difficile infections, with particular attention to prevention and management in patients with IBD.

Chronic Diarrhea: Is it Infectious?
Christina M. Surawicz, MD, MACG
Analyze the GI pathogen testing and treatment strategies for patients presenting with chronic diarrhea and SIBO.

Gastroenterology Consultation in the Returning International Traveler
Bradley A. Connor, MD
Define a strategy for the efficient evaluation of patients with gastrointestinal syndromes after international travel.

The Microbiome: What the Gastroenterologist Needs to Know and What the Future Holds
Baharak Moshiree, MD, MS-CI
Summarize the biotechnologies and informatics used to analyze the gut microbiome, and the near-term implications for human health and disease.
Pearls With a Master
David A. Johnson, MD, MACG
Summarize key clinical pearls for GI care and describe how to apply them to practice.

Management of Cystic Lesions of the Pancreas
John R. Saltzman, MD, FACG
Discuss the guideline recommendations for the management of pancreatic cystic lesions.

The Management of Perianal Crohn's Disease
David A. Schwartz, MD, FACG
Define the appropriate evidence-based management of patients with perianal Crohn's Disease.

Challenging Eosinophilic Esophagitis Patients
Evan S. Dellon, MD, MPH
Explain the management options in difficult EoE patients in a case study format.

"Primary Care" for Cirrhotics
David E. Bernstein, MD, FACG
Identify the management, screening, and surveillance strategies for patients with cirrhosis.

Sunday, December 4, 2016

SESSION 4: THE GI HOSPITALIST: MANAGEMENT OF INPATIENT GI DISEASES
Moderator: John R. Saltzman, MD, FACG

The Exsanguinating Patient: New Tools and Recent Guidelines
John R. Saltzman, MD, FACG
Evaluate new technologies and incorporate guideline recommendations into the management of severe gastrointestinal hemorrhage.

Colon Ischemia: Endoscopy and Radiology in Diagnosis and Management
Lawrence J. Brandt, MD, MACG
 Explain the role of endoscopy and radiology in acute mesenteric vascular syndromes.

Management of the Hospitalized Cirrhotic: Updates and Pearls
Mitchell L. Shiffman, MD, FACG
Outline the management of severe alcoholic hepatitis in light of recent clinical trials. Translate literature-based strategies into practice to improve outcomes of inpatients with cirrhosis.

Practice Models for Inpatient GI Consultation
James S. Leavitt, MD, FACG
Describe practice models for hospitalized patients, including the role of full-time GI hospitalists and physician extenders.

SESSION 5: PREVENTION OF GASTROINTESTINAL CANCERS
Moderator: Carol A. Burke, MD, FACG

Colon Cancer Prevention: From FIT to ADRs
David A. Johnson, MD, MACG
Identify technologies and techniques for adenoma detection and colon cancer prevention.

Genetic Testing and Management of the Hereditary Gastrointestinal Cancer Syndromes
Carol A. Burke, MD, FACG
Discuss the recent guidelines and their practical implementation.

Precision Medicine in the Management of Gastric Intestinal Metaplasia
Douglas R. Morgan, MD, MPH, FACG
Interpret the biomarkers used to individualize GIM screening and surveillance.

Barrett’s Esophagus: Biomarkers, Ablation, and Surveillance
Evan S. Dellon, MD, MPH
Translate recent advances in the management and treatment of the Barrett's patient into practice.